Afatinib in Patients with Advanced HER2 Mutation-Positive (M plus ) NSCLC Previously Treated with Chemotherapy

被引：0
|
作者：
Zhou, Caicun [1 ]
Fan, Yun [2 ]
Wang, Huijuan [3 ]
Liam, Chong Kin [4 ]
Hu, Chengjie [5 ]
Cseh, Agnieszka [6 ]
机构：
[1] Shanghai Pulm Hosp, Med Oncol, Shanghai, Peoples R China
[2] Zhejiang Canc Hosp, Dept Chemotherapy, Hangzhou, Zhejiang, Peoples R China
[3] Zhengzhou Univ, Affiliated Canc Hosp, Henan Canc Hosp, Dept Internal Med, Zhengzhou, Henan, Peoples R China
[4] Univ Malaya Med Ctr, Dept Med, Kuala Lumpur, Malaysia
[5] Boehringer Ingelheim China Investment Co Ltd, Beijing, Peoples R China
[6] Boehringer Ingelheim Rcv GmbH & Co KG, Dept Med Affairs, Vienna, Austria
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 01期
关键词：
NSCLC; afatinib; HER2; phase II;
D O I：
10.1016/j.jtho.2016.11.1506
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.06-013
引用
收藏
页码：S1077 / S1077
页数：1
相关论文
共 50 条
  • [21] Erratum to: Predictive value of serum HER2 ECD in patients with HER2-positive advanced gastric cancer treated with trastuzumab plus chemotherapy
    Jun Zhou
    Zhi Peng
    Yi Liu
    Jifang Gong
    Xiaotian Zhang
    Ming Lu
    Jing Gao
    Yili Li
    Yanyan Li
    Lin Shen
    Journal of Gastroenterology, 2016, 51 : 509 - 510
  • [22] Sequential treatment with afatinib and osimertinib in real-world patients with EGFR mutation-positive advanced NSCLC: the GioTag study
    Hochmair, M.
    Cufer, T.
    Morabito, A.
    Hao, D.
    Yang, C. Ta
    Soo, R.
    Yang, J.
    Gucalp, R.
    Halmos, B.
    Wang, L.
    Golembesky, A.
    Maerten, A.
    O'Byrne, K.
    LUNG CANCER, 2019, 127 : S59 - S60
  • [23] Sequential treatment with afatinib and osimertinib in real-world patients with EGFR mutation-positive advanced NSCLC: the GioTag study
    Hochmair, M.
    Cufer, T.
    Morabito, A.
    Hao, D.
    Yang, C.
    Soo, R.
    Yang, J. C.
    Gucalp, R. Rasim
    Halmos, B.
    Wang, L.
    Golembesky, A.
    Maerten, A.
    O'Byrne, K.
    LUNG CANCER, 2019, 127 : S37 - S37
  • [24] Afatinib in Advanced Lung Squamous Cancer Harboring HER2 Mutation in Exon 17 Plus Amplification
    Wang, Yu-Ji
    Zeng, Da-Xiong
    AMERICAN JOURNAL OF THERAPEUTICS, 2024, 31 (05) : e594 - e596
  • [25] Afatinib followed by osimertinib in patients with EGFR mutation-positive (EGFRm plus ) advanced NSCLC: Updated data from the GioTag real-world study
    Hochmair, M. J.
    Morabito, A.
    Hao, D.
    Yang, C-T.
    Soo, R.
    Yang, J. C-H.
    Gucalp, R.
    Halmos, B.
    Wang, L.
    Golembesky, A.
    Maerten, A.
    Cufer, T.
    ANNALS OF ONCOLOGY, 2019, 30
  • [26] Investigation of dimer formation and intracellular dynamics of HER2 in HER2 mutation-positive lung cancer
    Shimauchi, Atsushi
    Tsutsumi, Hirono
    Iwama, Eiji
    Shibahara, Daisuke
    Yoneshima, Yasuto
    Tanaka, Kentaro
    Okamoto, Isamu
    CANCER SCIENCE, 2024, 115 : 797 - 797
  • [27] Afatinib in Asian and non-Asian patients (pts) with EGFR mutation-positive (EGFRm plus ) NSCLC harboring uncommon mutations
    Yang, J. C-H.
    Schuler, M.
    Popat, S.
    Miura, S.
    Heeke, S.
    Passaro, A.
    de Marinis, F.
    Park, K.
    Kim, E. S.
    ANNALS OF ONCOLOGY, 2020, 31 : S860 - S861
  • [28] Vinflunine plus trastuzumab in previously treated Her2 positive bladder cancer: A case report
    Rivera Rivera, Samuel
    Casarez Price, Juan Carlos
    GACETA MEXICANA DE ONCOLOGIA, 2016, 15 (04): : 240 - 244
  • [29] Analysis of Prognostic Factor for Afatinib Treated Patients with EGFR Mutation Positive NSCLC
    Sata, Masafumi
    Kato, Terufumi
    Manabe, Saki
    Murakami, Shuji
    Kondo, Tetsuro
    Saito, Haruhiro
    Sekine, Akimasa
    Ogura, Takashi
    Yamada, Kouzo
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1210 - S1211
  • [30] Investigation of intracellular dynamics of HER2 and effect of HER2-ADC in HER2 mutation-positive lung cancer
    Shimauchi, Atsushi
    Iwama, Eiji
    Ibusuki, Ritsu
    Shibahara, Daisuke
    Otsubo, Kohei
    Yoneshima, Yasuto
    Okamoto, Isamu
    CANCER SCIENCE, 2025, 116 : 231 - 231
12345